**Supplementary Table 2.** Efficacy and safety of oral anticoagulant and antiplatelet therapies

| Independent variable | Stroke | Recurrent IS | ICH | All-cause death | MACE |
|----------------------|--------|--------------|-----|----------------|------|
| **All patients**     |        |              |     |                |      |
| Antiplatelet therapy | Reference | Reference   | Reference | Reference | Reference |
| Anticoagulants       | 0.42 (0.23–0.76) | 0.39 (0.20–0.76) | 0.72 (0.24–2.15) | 0.71 (0.42–1.22) | 0.46 (0.27–0.80) |
| VKA                 | 0.48 (0.26–0.88) | 0.42 (0.21–0.85) | 0.83 (0.28–2.57) | 0.71 (0.41–1.25) | 0.53 (0.30–0.93) |
| NOACs               | 0.22 (0.06–0.74) | 0.27 (0.08–0.92) | 0.31 (0.04–2.89) | 0.73 (0.35–1.52) | 0.24 (0.08–0.72) |
| **Patients with multiple CMBs** |        |              |     |                |      |
| Antiplatelet therapy | Reference | Reference   | Reference | Reference | Reference |
| Anticoagulants       | 0.38 (0.19–0.75) | 0.37 (0.17–0.82) | 0.49 (0.16–1.50) | 0.49 (0.26–0.95) | 0.38 (0.20–0.74) |
| VKA                 | 0.43 (0.22–0.87) | 0.40 (0.18–0.92) | 0.54 (0.17–1.73) | 0.44 (0.22–0.89) | 0.45 (0.23–0.87) |
| NOACs               | 0.21 (0.05–0.89) | 0.28 (0.06–1.24) | 0.31 (0.04–2.62) | 0.69 (0.29–1.67) | 0.17 (0.04–0.76) |
| **Patients with strictly lobar CMB** |        |              |     |                |      |
| Antiplatelet therapy | Reference | Reference   | Reference | Reference | Reference |
| Anticoagulants       | 0.36 (0.17–0.75) | 0.37 (0.16–0.89) | 0.50 (0.16–1.59) | 0.96 (0.46–1.97) | 0.51 (0.25–1.01) |
| VKA                 | 0.41 (0.19–0.88) | 0.40 (0.16–1.01) | 0.57 (0.17–1.87) | 0.99 (0.47–2.09) | 0.57 (0.28–1.17) |
| NOACs               | 0.21 (0.05–0.93) | 0.29 (0.06–1.32) | 0.30 (0.03–2.66) | 0.91 (0.34–2.45) | 0.31 (0.09–1.09) |

IS, ischemic stroke; ICH, intracerebral hemorrhage; MACE, major adverse cardiovascular events; VKA, vitamin K antagonist; NOAC, non-vitamin K antagonist oral anticoagulant; CMB, cerebral microbleed.

---

**Supplementary Figure 1.** Subject enrollment flowchart. MRI, magnetic resonance imaging.